research on clinical recovery and maintenance strategies for chb

Conditions: Chronic Hepatitis b; Hepatitis B Vaccine

Summary: collect basic information of patients before antiviral treatment and when hbsag disappears, and divide them into three groups a, b, and c based on baseline anti hbs titers after informed consent. during the follow-up period of all patients, clinical biochemistry, virology (hbvdna, hbvrna), serological indicators (hbsag, anti hbs, hbeag, anti hbe, hbcrag, anti hbc), afp, fibroscan, liver imaging examinations will be conducted every 3-6 months, and blood samples will be retained for monitoring the frequency of immune cells (pdc, treg) and the expression of functional molecules, as well as cytokines (ifn - γ, ip-10, il-10, and tgf - β). observe the sustained response rate and recurrence rate of virological and serological indicators, as well as the incidence of hepatitis and liver cancer during the follow-up period.

collect basic information of patients before antiviral treatment and when hbsag disappears, and divide them into three groups a, b, and c based on baseline anti hbs titers after informed consent. group a has an anti hbs titer ≥ 100miu/ml and is followed up every 3-6 months for observation. the anti hbs titers\<100miu/ml were randomly divided into two groups: group b and group c. group b did not intervene and was followed up every 3-6 months for observation; in group c, 20 micrograms of recombinant hepatitis b vaccine were injected subcutaneously three times on day 0, january and march. for group c patients, the level of anti hbs was detected at the 4th month after the initial vaccination. for those who could not produce anti hbs (anti hbs\<10miu/ml), the recombinant hepatitis b vaccine was subcutaneously injected three times, 20 μ g each time, in 0 day, january and march. during the follow-up period of all patients, clinical biochemistry, virology (hbvdna, hbvrna), serological indicators (hbsag, anti hbs, hbeag, anti hbe, hbcrag, anti hbc), afp, fibroscan, liver imaging examinations were conducted every 3-6 months, and blood samples were retained for monitoring the frequency of immune cells (pdc, treg) and the expression of functional molecules, as well as cytokines (ifn - γ, ip-10, il-10, and tgf - β). observe the sustained response rate and recurrence rate of virological and serological indicators, as well as the incidence of hepatitis and liver cancer during the follow-up period.

Eligibility criteria:
inclusion criteria: * age between 18 and 65 years old; * gender is not limited; * chb patients who meet the diagnostic criteria of the 2019 edition of the guidelines for the prevention and treatment of chronic hepatitis b \[5\]; * confirmed interferon treatment resulted in hbsag disappearance, hbeag negativity, and hbv dna below the lower detection limit and cessation patients treated with interferon; * sign a written informed consent form. exclusion criteria: * merge with other hepatitis virus (hcv, hdv) infections; * autoimmune liver disease; * hiv infection; * long term alcohol abuse and/or other liver damaging drugs; * mental illness; * evidence of liver tumors (liver cancer or afp\>100ng/ml); * decompensated cirrhosis; * individuals with serious diseases of the heart, brain, lungs, kidneys, and other systems who cannot participate in long-term follow-up.